Baxter International BAX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Healthcare Systems & Technologies | $705M-14.8% | $827M+7.0% | $773M+0.8% | $767M+8.9% | $704M-10.2% | |
| Medical Products & Therapies | $1.29B-7.4% | $1.39B+4.4% | $1.33B+0.7% | $1.32B+4.6% | $1.26B-4.0% | |
| Pharmaceuticals | $621M-7.0% | $668M+5.7% | $632M+3.3% | $612M+5.3% | $581M-9.6% | |
| Net Sales by Product | ||||||
| Advanced Surgery | $304M-7.3% | $328M+7.2% | $306M+3.4% | $296M+10.4% | $268M-8.2% | |
| Care & Connectivity Solutions | $435M-19.0% | $537M+13.5% | $473M-0.2% | $474M+11.0% | $427M-15.3% | |
| Drug Compounding | $320M+1.3% | $316M+5.7% | $299M+6.8% | $280M+13.8% | $246M-5.4% | |
| Front Line Care | $270M-6.9% | $290M-3.3% | $300M+2.4% | $293M+5.8% | $277M-1.1% | |
| Infusion Therapies & Technologies | $981M-7.5% | $1.06B+3.6% | $1.02B-0.1% | $1.02B+3.0% | $994M-2.7% | |
| Injectables & Anesthesia | $301M-14.5% | $352M+5.7% | $333M+0.3% | $332M-0.9% | $335M-12.5% | |
| Net Sales by Geography | ||||||
| International | $1.27B-11.0% | $1.42B+10.1% | $1.29B+1.3% | $1.27B+12.2% | $1.14B-8.7% | |
| United States | $1.44B-7.5% | $1.55B+0.5% | $1.54B+0.5% | $1.54B+3.1% | $1.49B-1.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Baxter International break its business down?
- Baxter International (BAX) reports net sales by business across 3 parts — Healthcare Systems & Technologies, Medical Products & Therapies and Pharmaceuticals. Each is extracted from the segment footnotes and tracked over time.
- Where does Baxter International's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Baxter International's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
